Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz KöR

7 trials 3 recruiting Academic / non-commercial Merged from 2 name variants

Filter these 7 trials by condition, phase, country and more.

Open in Search →

7 Registered trials

3 Recruiting

4 Completed trials

2 Countries active

15 Unique IMPs

100% Results reported

Phase II

Phase IV

Phase I

Phase II: 5 Phase IV: 1 Phase I: 1

Oversight events:

2 temporary halts 1 corrective measure across 3 trials

View oversight register →

100%

4 of 4 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

B-cell lymphoma refractory 1 Small cell lung cancer limited stage 1 Rectal cancer stage III 1 Rectal cancer stage II 1 Neuroendocrine carcinoma 1

Top IMPs

AFATINIB 1 AVELUMAB 1 CABOZANTINIB 1 DURVALUMAB 1 IBRUTINIB 1 OSIMERTINIB 1 TAFASITAMAB 1 TISLELIZUMAB 1 VENETOCLAX 1

All trials

7 total

Total Neoadjuvant Treatment with or without Tislelizumab for Locally Advanced Rectal Cancer: An Open-label Randomized Controlled Phase II St… Recruiting

2025-522120-28-00 Phase II 1 country TISLELIZUMAB
Randomized, double-blind, placebo-controlled Phase I study in healthy individuals on autotaxin-inhibition with MJK2134025 in single-ascendin… Recruiting

2024-513116-10-00 Phase I 1 country
Venetoclax in combination with Ibrutinib and Rituximab or conventional chemotherapy (Bendamustine) and Ibrutinib and Rituximab in patients w… Recruiting

2022-501808-96-00 Phase II 2 countries IBRUTINIB; VENETOCLAX
AFAMOSI: Prospective, randomized, multicenter Phase IV study to evaluate the efficacy and safety of afatinib followed by osimertinib compare… Ended

2024-511625-55-00 Phase IV 1 country AFATINIB; OSIMERTINIB
A phase II trial investigating Gemcitabine/Oxaliplatin/Rituximab with Tafasitamab (MOR208) for patients aggressive Lymphoma. Ended

2024-514775-17-00 Phase II 1 country TAFASITAMAB
A study on the efficacy and safety of cisplatin/etoposide and concomitant radiotherapy in combination with durvalumab, an immunotherapy, in … Ended

2024-513433-20-00 Phase II 1 country DURVALUMAB
Cabozantinib in combination with Avelumab in patients refractory to standard chemotherapy with advanced neuroendocrine neoplasias G3 (NEN G3… Ended

2024-513518-37-00 Phase II 1 country AVELUMAB; CABOZANTINIB

Showing 1–7 of 7 trials

← All sponsors A–Z